Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Selenocysteine lyase is a pyridoxal 5'-phosphate-dependent enzyme that specifically catalyzes the decomposition of L-selenocysteine to L-alanine and elemental selenium (selenide), contributing to the recycling of selenium from the degradation of selenoproteins[1][2][3][4][5][6][7]. It exhibits strict substrate specificity for L-selenocysteine and does not act on L-cysteine. Selenocysteine lyase is found primarily in the liver and kidney, usually as a homodimer in mammals, and plays a crucial cellular role in selenium metabolism and homeostasis by providing a source of selenide for new selenoprotein biosynthesis[7][3]. Its molecular structure includes a conserved catalytic cysteine residue essential for substrate specificity, and its activity is vital for maintaining optimal selenium levels in organisms[3][1]. There are no current drugs targeting selenocysteine lyase, nor is it a recognized direct therapeutic target or disease biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Selenocysteine lyase (SCL).